Tolerance induction by 'megadose' transplants of CD34+ stem cells: a new option for leukemia patients without an HLA-matched donor.
Early studies in murine models and more recent clinical data in heavily pre-treated leukemia patients have shown that escalation of the dose of hematopoietic progenitor cells can overcome major genetic barriers and enable rapid and durable engraftment of haploidentical, three-locus-mismatched transplants without graft-versus-host disease. In vitro studies suggest that veto cells within the progenitor population most probably mediate this facilitating effect.
Reisner
Y
Y
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. Yair.Reisner@weizmann.ac.il
Martelli
M F
MF
D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis*; D006086:Graft vs Host Disease / Q000517:prevention & control; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D007938:Leukemia / Q000628:therapy*; D023001:Transplantation Tolerance
D018952:Antigens, CD34